Red Wine, Resveratrol and Atrial Fibrillation.
Laura Siga StephanEduardo Dytz AlmeidaMelissa Medeiros MarkoskiJuliano GaravagliaAline MarcadentiPublished in: Nutrients (2017)
Atrial fibrillation (AF) is a common cardiac arrhythmia that is associated with increased risk for cardiovascular disease and overall mortality. Excessive alcohol intake is a well-known risk factor for AF, but this correlation is less clear with light and moderate drinking. Besides, low doses of red wine may acutely prolong repolarization and slow cardiac conduction. Resveratrol, a bioactive polyphenol found in grapes and red wine, has been linked to antiarrhythmic properties and may act as an inhibitor of both intracellular calcium release and pathological signaling cascades in AF, eliminating calcium overload and preserving the cardiomyocyte contractile function. However, there are still no clinical trials at all that prove that resveratrol supplementation leads to improved outcomes. Besides, no observational study supports a beneficial effect of light or moderate alcohol intake and a lower risk of AF. The purpose of this review is to briefly describe possible beneficial effects of red wine and resveratrol in AF, and also present studies conducted in humans regarding chronic red wine consumption, resveratrol, and AF.
Keyphrases
- atrial fibrillation
- catheter ablation
- oral anticoagulants
- left atrial
- left atrial appendage
- direct oral anticoagulants
- cardiovascular disease
- clinical trial
- heart failure
- left ventricular
- percutaneous coronary intervention
- high intensity
- alcohol consumption
- type diabetes
- skeletal muscle
- physical activity
- metabolic syndrome
- coronary artery disease
- reactive oxygen species
- acute coronary syndrome
- insulin resistance
- open label
- tissue engineering